The writing group included representatives from the ACCF, AHA, American Academy of Family Physicians, American College of Emer- gency Physicians, American College of Physicians, Society for Cardiovascular Angiography and Interventions, and So- ciety of Thoracic Surgeons. 1.3. Document Review and Approval This document was reviewed by 2 official reviewers each nominated by the ACCF and the AHA, as well as 1 or 2 reviewers each from the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons, and 29 individual content reviewers, including members of the ACCF Interventional Scientific Council. The information on reviewers RWI was distributed to the writing group and is published in this document (Appendix 2). This document was approved for publication by the governing bodies of the ACCF and the AHA and endorsed by the American College of Emergency Physicians, Soci- ety for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. 3. Early Hospital Care 3.2. Antiplatelet/Anticoagulant Therapy in Patients for Whom Diagnosis of UA/NSTEMI Is Likely or Definite: Recommendations 3.2.1. Antiplatelet Therapy: Recommendations Supplement.) 3.2.3. Additional Management of Antiplatelet and Anticoagulant Therapy: Recommendations Supplement.) 3.2.3.1. Antiplatelet/Anticoagulant Therapy in Patients for Whom Diagnosis of UA/NSTEMI Is Likely or Definite tor therapy is an important component of antiplatelet therapy in patients with UA/NSTEMI and has been tested in several large trial populations with UA/NSTEMI. The last version of the guideline recommended the use of clopidogrel in patients with UA/NSTEMI because it was the only US Food and Drug Administration (FDA) approved P2Y12 receptor inhibitor in this patient population at that time.6 Since the publication of the last guideline,6 the FDA has approved 2 additional P2Y12 receptor inhibitors for use in patients with UA/NSTEMI. 